Abstract Background: DNA topoisomerase II inhibitors and poisons are among the most efficacious drugs for the treatment of cancer. Sensitivity of cancer cells to the cytotoxic effects of topoisomerase II targeting agents is thought to depend on the expression of the topoisomerase IIa isoform, and drug resistance is often associated with loss or mutation of topoisomerase IIa. Histone deacetylase inhibitors (HDACi) are a novel class of compounds that potentiate the antitumor effects of topoisomerase II^targeting agents. Methods: The interaction between HDACi and topoisomerase II^targeting agents in cancer cells was evaluated as a function of topoisomerase IIa and topoisomerase IIh expression. Topoisomerase II isoforms were selectively depleted using small interfering RNA and antisense. Druginduced formation of cleavable complexes involving topoisomerase IIa and topoisomerase IIh was evaluated by trapped-in-agarose DNA immunostaining and band depletion assays in the presence and absence of HDACi. Results: Preexposure to HDACi increased the cytotoxicity of topoisomerase II poisons.This was associated with a down-regulation of topoisomerase IIa expression but had no effects on topoisomerase IIh. In the setting of HDACi-induced chromatin decondensation and topoisomerase IIa depletion, topoisomerase II poison cytotoxicity was mediated through topoisomerase IIh cleavable complex formation. The HDACi-induced sensitization was also observed in cells with targetspecific resistance to topoisomerase II poisons. Conclusions: The recruitment of topoisomerase IIh as a target may overcome primary or emergent drug resistance to topoisomerase II^targeting agents and hence may broaden the applicability of this important class of anticancer agents.
Type II topoisomerases are essential enzymes that regulate the topological state of DNA to facilitate several biological processes. Topoisomerase II exists in two isoforms, topoisomerase IIa and topoisomerase IIh. Although these enzymes have high sequence homology (1) and a similar mechanism of action (2), they are regulated independently and have been associated with different cellular functions. Topoisomerase IIa is necessary for many biological processes involving doublestranded DNA, including replication, mitosis, and chromatin condensation (3, 4) . Topoisomerase IIa is mainly located in the nucleus and peaks in expression during G 2 -M (5, 6). In contrast, topoisomerase IIh expression remains stable throughout the cell cycle (7) and may have an important role in transcription (8) . Although it was reported that topoisomerase IIh may not be essential in mitosis, topoisomerase IIa knockdown experiments have shown that topoisomerase IIh may only partially substitute topoisomerase IIa during chromatin decondensation and cell segregation (9) .
Due to their essential roles, topoisomerase II enzymes have been successfully targeted for the treatment of cancer. To maintain genetic integrity during the cleavage and religation of DNA, both topoisomerase isoenzymes form transient bonds with the cleaved DNA called the cleavable complex (10) . The stabilization and persistence of these cleavable complexes by topoisomerase II poisons have been associated with DNA damage and cell death (11, 12) . Multiple in vitro and in vivo studies have suggested that sensitivity of tumor cells to topoisomerase II poisons depends on access to the targets, as well as target location and expression levels. For clinical use, topoisomerase IIa has been considered the more relevant target (13 -17) .
A class of drugs that may enhance access to DNA and thereby increase the antitumor activity of topoisomerase II -targeting agents are the histone deacetylase inhibitors (HDACi; refs. 14, 18, 19) . We previously reported a sequence-specific and timedependent potentiation of topoisomerase II -targeting agents by the HDACi, suberoylanilide hydroxamic acid (SAHA), and valproic acid (14, 20) . Our data indicated that prolonged treatment of cancer cells with an HDACi resulted in the depletion of proteins involved in the maintenance of heterochromatin and led to subsequent chromatin decondensation. Chromatin decondensation increased the access of topoisomerase II -targeting agents to the DNA substrate, which potentiated cell death induced by topoisomerase II -targeting agents. Topoisomerase II drug cytotoxicity is largely dependent upon topoisomerase IIa expression. Here, we investigated the relevance of topoisomerase IIa and topoisomerase IIh as targets of topoisomerase II poisons in the presence of HDACi. We show that in the setting of HDACi pretreatment, the formation of cleavable complexes involving topoisomerase IIh rather than topoisomerase IIa leads to topoisomerase II poison -induced cell death. This may broaden the clinical applicability of topoisomerase II poisons and overcome drug resistance due to acquired depletion and mutations of topoisomerase IIa.
Materials and Methods
Chemicals and antibodies. Trichostatin A, sodium butyrate (NaB), valproic acid, mitoxantrone, and teniposide (VM-26) were purchased from Sigma Chemical Co. (St. Louis, MO). SAHA was provided by Aton Pharma (Merck, Whitehouse Station, NJ). Epirubicin was purchased from Pfizer, Inc. (New York, NY). XK469 was a kind gift from Dr. Robert Snapka. All other reagents were of analytic grade and purchased from standard suppliers. Antibodies used were as follows: Ki-S1 (monoclonal, Chemicon, Temecula, CA) and 454 (polyclonal, developed by Dr. Dan Sullivan) for topoisomerase IIa, anti-topoisomerase IIh (monoclonal, BD Biosciences, San Jose, CA) and JAB (polyclonal, developed by Dr. Dan Sullivan), and acetylated histone H3 antibody (Upstate Biotechnology, Chicago, IL).
Cell lines. SKBr-3, MCF-7, KM12C, A375, BT-474, and MDA-MB-361 cells were purchased from the American Type Culture Collection (Manassas, VA). Doxorubicin-resistant MCF-7 cells (MCF:Dox) were a kind gift from Dr. Fred Hausheer. Cell lines were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mmol/L glutamine, and 50 units/mL penicillin, and 50 Ag/mL streptomycin (Life Technologies Bethesda Research Laboratories, Carlsbad, CA). Cells were incubated in a humidified atmosphere with 5% CO 2 at 37jC.
Cytotoxicity assays. Topoisomerase II poison cytotoxicity was evaluated in the presence of HDACi by apoptotic and clonogenic assays.
Apoptosis was scored by the presence of nuclear chromatin condensation and DNA fragmentation and evaluated with fluorescence microscopy using bis-benzimide staining. Briefly, cells were treated with an HDACi for 48 hours, after which the media was removed and replaced with media containing the indicated concentrations of a topoisomerase II poison. After 4 hours, the topoisomerase II poison was removed, and the cells were cultured for an additional 48 hours. Cells were harvested using a Cell Scraper (Fisher, Hampton, NH), fixed in 4% paraformaldehyde for 10 minutes at room temperature, and washed with PBS. Cell nuclei were stained with 0.5 Ag/mL of bisbenzimide trihydrochloride (Hoechst #33258, Molecular Probes, Eugene, OR). Two hundred cells were counted for each experiment and evaluated for apoptotic scores (apoptotic nuclei/all nuclei Â 100). Each experiment was repeated thrice, and the SE was calculated.
For clonogenic assays, cells were plated on six-well dishes at a density of 150 per well and allowed to adhere for 24 hours. For drug combination studies, cells were incubated with medium containing 0.5 mmol/L valproic acid. At this concentration of valproic acid, valproic acid had no discernable effects on growth or apoptosis. After a 48-hour treatment with valproic acid, the medium was removed and replaced with medium containing 0, 1, 10, 25, 50, or 100 nmol/L epirubicin for 4 hours. Epirubicin was then removed, and colonies were allowed to grow for 14 to 21 days to a maximal size of 2 to 3 mm in diameter, stained with 2% crystal violet in methanol, and counted. Colonies were included in the assessment if measuring at least 0.2 mm. For single-drug samples and untreated controls, saline was used in lieu of valproic acid or epirubicin or both. All experiments were done in duplicates and repeated at least thrice. The concentration of epirubicin required for IC 50 was determined using the CalcuSyn software as described previously (14) . Synergistic effects versus additive effects were also determined by the CalcuSyn program. The fractional inhibition of valproic acid was depicted as the number of observed cells (treatment group) divided by the number of expected cells (untreated control) with a range of 0 to 1.
Microarray. Expression levels of topoisomerase IIa mRNA were evaluated by microarray analysis using Affymetrix Genechips (Affymetrix, Santa Clara, CA) by standard protocols (Moffitt, Molecular Biology Core). Hybridization to Affymetrix chips was analyzed using Affymetrix Microarray Suite 5.0 software. Signal intensity was scaled to an average intensity of 500 before comparison analysis. The MAS 5.0 software uses a statistical algorithm to assess changes in mRNA abundance in a direct comparison between two samples (Statistical algorithms description document. http://www.affymetrix. com/support/technical/whitepapers.affx). This analysis is based on the behavior of 16 different oligonucleotide probes designed to detect the same gene. Using the programmed default values, probe sets that yielded a change P < 0.04 were identified as changed (increased or decreased), and those that yielded a P between 0.04 and 0.06 were identified as marginally changed.
Western blot analysis. Samples were prepared using SDS lysis buffer [2% SDS, 10% glycerol, 0.06 mol/L Tris (pH 6.8)] and evaluated for protein concentration using the bicinchoninic acid method (Pierce, Rockford, IL). Proteins (50 Ag) were separated on 8% SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked in tris-buffered saline containing 0.05% Tween 20 (TBST), 5% nonfat milk and incubated with primary antibody in TBST, 5% nonfat milk, overnight at 4jC. Membranes were washed thrice for 10 minutes with TBST and incubated with the appropriate secondary antibody in TBST, 5% nonfat milk for 90 minutes at room temperature. Antibody binding was visualized by chemiluminescence on autoradiography film. Relative expression of proteins was determined by densitometry analysis of at least two scanned autoradiography films from independent experiments using Photoshop software.
Immunofluorescence. MCF-7 cells were treated with 2 mmol/L valproic acid for 48 hours. Cells were harvested by trypsinization, washed in PBS, and adhered to glass slide using Cytospin Funnels (Shandon, Pittsburgh, PA) at a density of 1 Â 10 5 /mL. Slides were blocked with 2% bovine serum albumin (BSA) in PBS for 1 hour and probed with antibodies specific for topoisomerase IIa, KiS1 (monoclonal, 1:50), and acetylated histone H3 (polyclonal, 1:100) in 1% BSA/PBS for 1 hour at room temperature in a humidified chamber. Slides were washed in PBS and incubated with anti-rabbit Alexa Fluor 488 and anti-mouse Alexa Fluor 546 (Molecular Probes) diluted 1:100 in 1% BSA/PBS containing goat serum for 1 hour at room temperature in a humidified chamber. Slides were washed with PBS and coverslipped using Prolong Gold mounting media (Molecular Probes). Images were acquired by confocal microscopy. The square pixel surface area for the respective protein expression was analyzed in at least 50 cells per treatment using Photoshop software. For each measured nucleus, the background staining was measured in the immediate vicinity and subtracted from the average square pixel surface area. Evaluation of secondary antibody staining only served as internal staining control. Levels for the fluorescence detection were set accordingly. Experiments were repeated at least twice.
Antisense/small interfering RNA. Topoisomerase IIa and topoisomerase IIh protein expression was blocked with antisense oligonucleotides and small interfering RNA (siRNA) duplexes. Antisense: The DNA sequences for the oligonucleotide probes were as follows: 5V -CTGCAATGGTGACACTTCCAT-3V for topoisomerase IIa and 5V -TTTGTAGTGGACAGAAACACAGTA-3V for topoisomerase IIh as described by Towatari et al. (21) . Oligonucleotide (1 Ag) was suspended in 100 AL Optimem (Life Technologies Bethesda Research Laboratories) containing 2 AL Superfect transfection reagent (Qiagen, Valencia, CA). The oligonucleotide suspension was raised to a total volume of 700 AL by the addition of DMEM containing 10% fetal bovine serum and incubated on cell monolayers (1 Â 10 5 cells) for 24 hours. The oligonucleotide mixture was replaced the following day, and the cells were incubated for an additional 4 hours before experimental procedures. Controls included topoisomerase IIa and topoisomerase IIh sense oligonucleotides as well as incubation of cells with Superfect in the absence of oligonucleotide. siRNA: RNA duplexes for topoisomerase IIa (sense, GGUAUUCCUGUUGUU-GAAC) and topoisomerase IIh (sense, GGUUACCUUUGUGC-CAGGU) were purchased from Ambion (Austin, TX). Cells were suspended in 0.1 mL siPort electroporation buffer (3 Â 10 6 /mL, Ambion), mixed with 1 Ag siRNA, and pulsed with 300 V for 0.5 milliseconds. Pulsed cells were incubated at 37jC for 15 minutes before experimentation. The Silencer Negative Control #2 siRNA (Ambion), a nonsense siRNA duplex, was used as a control.
Trapped-in-agarose DNA immunostaining assay. The trapped-inagarose DNA immunostaining assay (TARDIS) was done as described by Willmore et al. (22) BSA for 10 minutes, dried, and counterstained with 0.5 Ag/mL of bisbenzimide trihydrochloride (Hoechst #33258, Molecular Probes). Images were acquired by confocal microscopy and the square pixel surface area of the respective protein was analyzed for a minimum of 50 cells per treatment group. Statistical analysis was done by ANOVA. Experiments were repeated at least twice.
Band depletion. The band depletion assay was done as described by Xiao et al. (8) . Briefly, 5 Â 10 5 cells were lysed in alkaline lysis solution (200 mmol/L NaOH, 2 mmol/L EDTA), and the lysate was neutralized [neutralization buffer: 1 mol/L HCl, 600 mmol/L Tris (pH 8.0)]. The neutralized lysate was then mixed with 3Â SDS sample buffer [150 mmol/L Tris-HCl (pH 6.8), 6 mmol/L EDTA, 45% sucrose, 9% SDS, 10% h-mercaptoethanol], and the lysates were separated on 8% SDS-PAGE gels.
Results
Interactions of topoisomerase II poisons and histone deacetylase inhibitors. We previously reported an increased sensitivity of tumor cells to topoisomerase II -targeting agents after pretreatment with an HDACi in vitro and in vivo (14, 20) . Treatment with HDACi led to dose-and time-dependent histone acetylation and subsequent modulation of genes and proteins essential for the maintenance of heterochromatin. The ensuing chromatin decondensation was associated with an increased binding of topoisomerase II poisons to the DNA substrate and in the presence of topoisomerase II, with increased DNA damage and cell death.
The sensitivity of cancer cells to topoisomerase II -targeting agents has been linked to expression of the topoisomerase IIa isoform, whereas studies on the role of topoisomerase IIh have been more limited. Our experimental data indicate that preexposure of tumor cells to HDACi potentiates the apoptosis induced by the topoisomerase II poisons epirubicin and mitoxantrone (Fig. 1A) . Potentiation was not limited to a certain class of HDACi and was observed with selective (SAHA and trichostatin A) as well as with nonselective (valproic acid) HDACi. Similarly, potentiation occurred with other topoisomerase II -targeting agents, such as doxorubicin, etoposide, and VM-26 (see below; data not shown; and refs. 14, 20) .
Densitometry analysis of Western blots (n = 3) evaluating cancer cells derived from different organs, including breast, colon, and melanoma, showed that the examined cell lines with decreased or mutated topoisomerase IIa, required higher concentration of epirubicin for IC 50 (Table 1) as assessed by colony-forming assays. As reported by other investigators, these data suggest that not organ specificity but rather expression of the topoisomerase II isoforms was predictive for response (13) .
A 48-hour preexposure of these cells to the HDACi valproic acid resulted in a decrease in the IC 50 of epirubicin. The concentration of valproic acid used for these experiments affected <10% of cells, resulting in a fractional inhibition of cell growth by valproic acid alone of F i < 0.1 compared with untreated cells (Table 1) . Isobologram analysis using the CalcuSyn software suggested the interaction between valproic acid and epirubicin was synergistic in SKBr3, MCF-7, A375, BT-474, KM12C, and MCF:Dox cells (data not shown). A decrease in IC 50 was not observed in MDA-361 cells with a near depletion of both topoisomerase II isoforms topoisomerase IIa and topoisomerase IIh. In contrast, in the epirubicin-resistant cell line MCF:Dox, the IC 50 of epirubicin was lowered by valproic acid despite a mutation and down-regulation of the Topoisomerase IIa expression is down-regulated by histone deacetylase inhibitor. It is thought that sensitivity of cancer cells to topoisomerase II -targeting agents is predominantly mediated through topoisomerase IIa (13 -17) . However, we observed an HDACi-induced sensitization in cells with depleted topoisomerase IIa but not in cells depleted of both topoisomerase II isoforms. The effects of HDACi on the expression of topoisomerase IIa and topoisomerase IIh were evaluated across sensitive and resistant cell lines. As reported previously, we found that HDACi-induced sensitization of cells to topoisomerase II poisons was maximal after a 24-to 48-hour preexposure to the HDACi (14) . Time course evaluating the protein expression of topoisomerase IIa, topoisomerase IIh, and topoisomerase I showed that after a 48-hour exposure to 2 Amol/L SAHA, rather than an upregulation, a depletion of topoisomerase IIa protein was observed ( Fig. 2A) . The depletion of topoisomerase IIa expression was not limited to SAHA but was observed with the short-chain fatty acids valproic acid and NaB as well as the hydroxamic acid trichostatin A (Fig. 2B ). The decrease in nuclear protein expression corresponded to a time-dependent reduction in the expression of topoisomerase IIa mRNA (Fig. 2C) and not a change in cellular location (Fig. 2D) . Furthermore, HDACi had no significant effects on the expression of topoisomerase I and topoisomerase IIh ( Fig. 2A  and B) . Expression levels of topoisomerase IIa vary with alterations in cell cycle distribution with peak expression in G 2 -M. To rule out a causal link between HDACi-induced cell cycle block and the observed reduction in topoisomerase IIa expression, topoisomerase IIa levels were studied over a wide range of HDACi concentrations. Topoisomerase IIa was depleted at concentrations of HDACi that did not perturb cell cycle progression ( Fig. 2B ; data not shown), suggesting that HDACi-induced cell cycle arrest and HDACi-induced topoisomerase IIa depletion are independent events (data not shown). Furthermore, a SAHA-induced depletion of topoisomerase IIa was observed at concentration of SAHA (>5 Amol/L) that were shown to result in a G 2 -M arrest, the cell cycle phase where topoisomerase IIa is increased (23) .
Relevance of topoisomerase IIb as a target. Potentiation of topoisomerase II targeting agents by HDACi in the setting of topoisomerase IIa depletion argued for the involvement of the alternative topoisomerase II isoform topoisomerase IIh. Synergy between an HDACi and a topoisomerase II -targeting agent was preserved when using the topoisomerase IIh -specific poison, XK469, signifying a potential role of topoisomerase IIh as a target for drug therapy. A potentiation of XK469 by preexposure to valproic acid was found in several examined breast cancer cell lines, including SKBr-3, MCF-7, and the topoisomerase IIa -depleted MCF:Dox cells (Fig. 3A) . To further define the involvement of topoisomerase IIh in the interaction between HDACi and topoisomerase II poisons, both topoisomerase II isoforms were alternatively depleted by siRNA or antisense and exposed to HDACi before administration of a topoisomerase II poison. We have shown above that treatment with HDACi resulted in a down-regulation of topoisomerase IIa (Fig. 2) . Treatment of MCF-7 cells with siRNA resulted in significant depletion of topoisomerase IIa and topoisomerase IIh protein levels without affecting viability ( Fig. 3B ; data not shown). Topoisomerase IIa was further depleted with the addition of valproic acid (Fig. 3B) . Depletion of topoisomerase IIa by siRNA did not effect the potentiation of epirubicin, mitoxantrone, or VM-26 by valproic acid (Fig.  3C) . In contrast, the synergistic activity between HDACi and these topoisomerase II -targeting drugs was abrogated by the depletion of topoisomerase IIh (Fig. 3C ). These findings were mirrored when antisense was used to deplete topoisomerase IIa or topoisomerase IIh or when SAHA was used in lieu of valproic acid (data not shown).
Although the topoisomerase IIa siRNA was exquisitely specific, the topoisomerase IIh siRNA showed a slight offtarget effect on the expression of topoisomerase IIa. This offtarget effect unlikely contributed to the abrogation of synergy between valproic acid and topoisomerase II poisons because (14, 20) . Topoisomerase II poisons are thought to confer cytotoxicity through the stabilization of topoisomerase II/DNA cleavable complexes. We evaluated whether the presence of HDACi resulted in the involvement of a specific topoisomerase II isoform in the cleavable complexes stabilized by topoisomerase II poisons.
The cleavable complexes involving topoisomerase IIa or topoisomerase IIh induced by epirubicin in the presence and absence of a 48-hour pretreatment with 2 mmol/L valproic acid were evaluated by trapped-in-agarose DNA immunostaining assay.
Immunofluorescence analysis of confocal microscopy images showed that at concentrations of epirubicin with minimal effect on the stabilization of cleavable complexes involving topoisomerase IIa (P > 0.05), there was a 3-fold increase in the accumulation of topoisomerase IIh -containing cleavable complexes stabilized by epirubicin in the presence of valproic acid ( Fig. 4A and B) . This difference reached statistical significance (*, P < 0.001). Similar results were observed when mitoxantrone was used in lieu of epirubicin (data not shown). Valproic acid by itself did not induce the formation of cleavable complexes. As described above, valproic acid treatment results in depletion of topoisomerase IIa.
To further establish whether these findings were intrinsic to the anthracycline family members (intercalating topoisomerase II poisons), band depletion assays were performed using the nonintercalating topoisomerase II poison, VM-26. This drug has been reported to induce cell death with the preferential formation of topoisomerase IIa -containing cleavable complexes (24) . The band pattern of topoisomerase IIa and topoisomerase IIh was evaluated in MCF-7 cells exposed to VM-26 and the HDACi valproic acid (Fig. 4C) . Band depletion assays allow detection of topoisomerase IIa and topoisomerase IIh complexed with DNA. The topoisomerase enzymes that are covalently bound to DNA (cleavable complexes) are prohibited from entering the acrylamide gel resulting in a band depletion, whereas topoisomerase II enzymes not bound to DNA readily enter the gel. Exposure of cells to VM-26 resulted in a 52% depletion of topoisomerase IIh band, whereas no effects were seen with valproic acid alone. In cells preexposed to 2 mmol/L valproic acid, VM-26 induced an 81% reduction in the topoisomerase IIh band, suggesting an increase in cleavable complex formation Fig. 4C (bottom) .
VM-26 induced a 51% depletion in the topoisomerase IIa band. There was a 46% decrease in the topoisomerase IIa band after treatment with valproic acid alone. In cells treated with valproic acid before VM-26, there was a 92% depletion of the topoisomerase IIa band (Fig. 4C, top) . However, as discussed above, treatment with valproic acid resulted in a downregulation of topoisomerase IIa protein expression ( Fig. 2A  and B and Fig. 3B ). The further reduction in the topoisomerase IIa band by VM-26 in the presence of valproic acid resulted from the additive effects of the HDACi-induced downregulation of the protein and the loss of topoisomerase IIa band due to cleavable complex formation induced by VM-26. This is further supported by the trapped-in-agarose DNA immunostaining assay showing no increase in the topoisomerase IIa -cleavable complexes induced by valproic acid alone. These findings suggest that treatment of cell with valproic acid enhanced the formation of cleavable complexes involving topoisomerase IIh but not topoisomerase IIa in the presence of VM-26.
Discussion
Topoisomerase II is an essential enzyme for cell survival, and the increased expression of topoisomerase II in many cancer cells has made these enzymes attractive targets for cancer therapy. Topoisomerase II exists in two isoforms, topoisomerase IIa and topoisomerase IIh, with partial functional redundancy (9, 25 -28) . In yeast, either isoform may substitute for the endogenous topoisomerase II enzyme (29) . Murine transgenic studies have shown that although topoisomerase IIa may compensate for a loss of topoisomerase IIh during embryogenesis (30) , the loss of topoisomerase IIa leads to embryonic death (31) . However, topoisomerase IIh seems essential for neuromuscular development after birth (30) . In adult mammalian cells, disruption of topoisomerase IIh by siRNA has no detrimental effects on cell cycle progression. In addition, topoisomerase IIh may compensate, albeit only partially, for topoisomerase IIa during chromatin condensation and cell segregation (9, 32) . Despite similar catalytic activities of the topoisomerase II isoenzymes, cell survival has been correlated with the expression of topoisomerase IIa (12, 33) . The role of topoisomerase II as drug targets for topoisomerase II poisons has been evaluated in several studies; and it has been suggested that topoisomerase IIa is the relevant target of topoisomerase II poisons. Disruption or mutation of topoisomerase IIa was associated with drug resistance (34 -36) . In particular, there are several reports suggesting topoisomerase IIa to be an important target for epirubicin, the drug used predominantly for this study; however, much less is known about the role of topoisomerase IIh as a drug target for epirubicin (17) . There currently are several drugs approved for clinical use that predominantly target topoisomerase IIa, whereas the clinical utility of topoisomerase IIh -specific drugs is still under investigation (37) .
Here, we provide evidence that HDACi render topoisomerase IIh a relevant target and effector substrate for topoisomerase II poisons. We have shown that preexposure of tumor cells to HDACi led to histone acetylation and down-regulation of proteins essential for the maintenance of heterochromatin (20) . The ensuing chromatin decondensation was associated with increased binding of topoisomerase II poisons to the DNA substrate (14, 20) . The kinetics of the HDACi-induced chromatin decondensation suggested that a 48-hour preexposure was optimal for synergistic activity.
We now show that exposure of tumor cells to HDACi significantly reduced the concentrations of topoisomerase II poisons required for growth inhibition, even in cells manipulated for target-specific resistance to topoisomerase II -targeting agents. Sensitization was not tissue specific but was observed in breast, colon, leukemia, melanoma, and sarcoma cell lines. We observed a time-dependent reduction in the expression of topoisomerase IIa mRNA and protein in the presence of HDACi that was maximal at 48 hours. In contrast, the effects of HDACi on topoisomerase IIh were minimal. Modulation of the topoisomerase II isoforms with siRNA and antisense showed that depletion of topoisomerase IIh abrogated the HDACi-induced potentiation of topoisomerase II poisons, whereas the depletion of topoisomerase IIa did not affect this synergistic interaction. (14, 19, 20, 39, 40) . Synergy was dependent on sequence and timing of drug administration and associated with HDACi-induced chromatin decondensation (14, 19) .
Although topoisomerase IIa has been proposed as the effector molecule for cytotoxicity for topoisomerase II poison, the specific roles of topoisomerase IIa and topoisomerase IIh in the interaction between HDACi and topoisomerase II poisons have not been defined. Fig. 2B and Fig. 3B) . Therefore, the depletion of topoisomerase IIa in the VPA:VM-26 sample was a reflection of protein down-regulation by valproic acid and cleavable complex formation induced byVM-26 alone and did not signify an enhancement of VM-26-induced cleavable complex formation.
topoisomerase IIa mRNA and protein. Maximal effects only occurred after a prolonged exposure to the HDACi (48 hours). Topoisomerase IIa depletion was not limited to a specific HDACi class but was observed with both short-chain fatty acid and hydroxamic acid HDACi. In part, the differences between the findings presented in this report and those presented by others may be explained by differences in the duration of HDACi exposure. More importantly, these findings may also suggest a limited role of topoisomerase IIa in the observed synergy between an HDACi and a topoisomerase II poison. This is further supported by our findings showing that nearcomplete depletion of topoisomerase IIa by siRNA or antisense in the presence of an HDACi did not inhibit the potentiation of topoisomerase II poisons by HDACi. The HDACi-induced depletion of topoisomerase IIa mRNA and protein expression was maximal at 48 hours, which correlated to maximal HDACiinduced chromatin decondensation and the optimal timing of synergy between HDACi and topoisomerase II -targeting agents. Although topoisomerase IIa was reported to be involved in chromatin condensation (42) , a mechanistic link between the topoisomerase IIa depletion and chromatin decondensation cannot be established by the presented data.
More evidence suggesting topoisomerase IIh as a relevant target in the potentiation of topoisomerase II -targeting agents by HDACi emerges from studies using the topoisomerase IIhspecific poison XK469. XK469 was shown to induce cleavable complexes in several cell lines in vitro; however, meaningful effects on tumor burden in vivo were not achievable at tolerable doses (43) . We found that XK469 by itself only caused minimal apoptosis in breast cancer cells; however, when administered in a sequence-specific combination with HDACi, we observed a potentiation of XK469 induced apoptosis by HDACi. These experiments collectively imply that topoisomerase IIh is a relevant target in the interaction between HDACi and topoisomerase II -targeting agents. This is further supported by the findings that depletion of topoisomerase IIh abrogated the synergistic interaction, whereas depletion of topoisomerase IIa did not affect synergy.
Although topoisomerase IIh may be a target of selected topoisomerase II poisons (44 -46) , most reports suggest that the cytotoxicity for the clinically relevant topoisomerase IItargeting agents is determined by topoisomerase IIa levels (47 -50) . The data presented here show that HDACi potentiates the cytotoxicity of topoisomerase IIa and topoisomerase IIh -specific topoisomerase II poisons by recruiting topoisomerase IIh as a target. The results of this study may have several clinical implications. HDACi may lower the concentration of topoisomerase II targeting agents required for activity, thereby limiting adverse effects. Emerging drug resistance due to a loss or mutation of topoisomerase IIa may be circumvented by engaging topoisomerase IIh as an alternative target. A potentiation of cytotoxicity was not observed in fibroblast exposed to an HDACi before exposure to a topoisomerase II poison (data not shown). Furthermore, preliminary results from an ongoing phase I trial studying a combination of valproic acid and epirubicin did not suggest a potentiation of epirubicin-induced toxicity (Munster et al, ASCO 2005 #A3084) . The differential effects of this combination on somatic versus tumor cells may limit tissue-specific toxicities, such as anthracycline-associated cardiotoxicity. In addition, HDACi may increase the clinical utility of h-specific drugs.
